DOTZ NANO LIMITED (DTZ)

The suspension of trading in the securities of Dotz Nano Limited will be lifted from the commencement of trading on Monday, 15 March 2021, following the release of the following DTZ announcements: "˜Business Update'- released 1 March 2021; "˜Retraction and clarification of statements'- released 1 March 2021; "˜Response to ASX Query- certain disclosure matters'- released 12 March 2021; and "˜Response to ASX Query- early release of information'- released 12 March 2021.

The company releases a response to ASX Query- early release of information.

The company releases a response to ASX Query- certain disclosure matters.

The company's Chairman and Interim CEO, Mr Bernie Brookes AM, on 4 December 2020, participated in a webinar presentation in relation to the Company hosted by Spark PE with a small number of overseas investors. Due to a breakdown in the Company's internal communication processes, some of the statements made did not accurately reflect the position as at the time of the Webinar. To ensure the market is fully informed, ASX has asked Dotz to retract and/or clarify some statements made by Mr Brookes during the Webinar.

As a result of initial work undertaken by Caerus, Dotz had proposed to enter into an Asset Purchase Agreement. Due to concerns raised by the ASX in relation to ASX Listing Rules 11.1.2 and 11.1.3, Dotz agreed to amend the Caerus Service Agreement on 28 February 2021 to ensure ongoing protection of its intellectual property rights in the Dotz Test Kit and to remunerate and incentivise Caerus as Dotz continues to pursue the development and commercialisation of the Dotz Test Kit with the assistance of Caerus. Under the Updated Caerus Service Agreement, Dotz will leverage Caerus' extensive diagnostic resources and expertise, including a state-of-the art laboratory, to continue to research and develop its own virus detection technology. Importantly, Dotz retains all intellectual property rights as well as any improvements in respect of the Dotz Test Kits. On 25 January 2021, Dotz obtained authorisation to use the CE mark for its Dotz Test Kits. Dotz has commenced a clinical trial of its virus detection technology with Excelya in Greece. Dotz has begun preparing for its FDA submission of the Dotz Test Kit, which is expected to be submitted by the end of March 2021. Dotz entered into a services agreement for manufacturing and regulatory consultancy with established US-based manufacturer Systaaq Diagnostic Products on 13 December 2020 to satisfy a key CE requirement and to prepare for commercialisation and production of the Dotz Test Kits. Dotz is also currently negotiating a manufacturing agreement for the Dotz Test Kits with Systaaq and is engaged in confidential negotiations with additional manufacturers in Canada and Asia.

The company lodges its Appendix 4E Preliminary Final Report - 31 December 2020.

Pages 73 - 77 of the Annual Report incorrectly contained the Additional Shareholder Information for the previous year. The company released the correct version of the Additional Shareholder Information for the year ended 31 December 2019.

The company lodges its Quarterly Report & Appendix 4C Cashflow Report - 31 Dec 2020.

The following securities are due to be released from escrow on 14 January 2021 as follows: UNL OP @$0.05 EXP 16/10/2022 (DTZOPT31) = 100,000 securities.

Dotz remains in discussions with the ASX in relation to an upcoming announcement and hopes to resolve all outstanding matters to the ASX's satisfaction as soon as possible.

Dotz is currently in discussions with ASX in relation to the acquisition and hopes to have all outstanding matters resolved as soon as possible.

The securities of Dotz Nano Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of DTZ, pending the release of an announcement.

The suspension of trading in the securities of Dotz Nano Limited will be lifted immediately, following the release by DTZ of an announcement regarding a sales contract.

Three-year agreement, automatically renewed for additional one year periods, with new Canada-based PPE manufacturer Breathe Medical Manufacturing Ltd, to supply Dotz's advanced "Secured by Dotz" authentication solution for respiratory face masks and other PPE equipment. Exclusivity granted to Breathe Medical to sell the "˜Secured by Dotz' solution for face masks in the USA and Canada, subject to minimum annual sales targets being met. Initial order of US$1 million due in Q1 2021 (January "“ March 2021). Q2 2021 and for the 10 subsequent quarters, minimum quarterly purchase orders of US$1.25 million, and minimum quarterly purchase orders of US$2.5 million to maintain exclusivity. For the initial three-year period of the agreement, the total minimum order amount is US$13 million, and to maintain exclusivity a total minimum amount of US$24.6 million. This agreement is the fourth PPE authentication agreement Dotz has secured in as many months, following distribution agreements with UEG in Hong Kong, V2Tech in Australia, and TT Medical Group across eight countries in Europe, Africa and the Middle East.

The securities of Dotz Nano Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of DTZ, pending the release of an announcement regarding a sales contract.

The suspension of trading in the securities of Dotz Nano Limited will be lifted immediately, following the release by DTZ of an announcement regarding a capital raising.

A$2 million Placement anchored by Australian-Israeli venture capital fund SIBF, new sophisticated Australian investors and existing shareholders. Additional A$1 million secured via a Deferred Share Placement from SIBF. Funds raised will be used to execute Dotz's commercialisation strategy, targeting endcustomers in the anti-counterfeiting, oil and gas and product liability sectors. Funding will enable Dotz to finalise advanced engagements with current prospects. Upon completion of this Placement, Dotz is well funded to execute its strategic plan. SIBF shall appoint a Director to the Board.

The company requests an extension to the voluntary suspension of its securities pending an announcement on the proposed share placement with a strategic investor. The announcement is expected to be made on 26 November 2019.

The securities of Dotz Nano Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of DTZ, pending the release of an announcement regarding the proposed share placement.

The suspension of trading in the securities of Dotz Nano Ltd will be lifted immediately, following

Firm commitments totaling A$1.5 million received. Strategic investor "Lions Investment" and Dotz major shareholders participate in the Placement. Funds raised will support Dotz Nano's next stage of growth, progressing sales opportunities in Plastics, Lubricants, Fuel and Fracking markets.

The company lodges a Quarterly CEO Update & Appendix 4C Cashflow Report - Mar 19.

The company anticipates that the suspension will remain in place until the release of an announcement regarding this capital raising, which is expected to be Tuesday, 30 April 2019.

The securities of Dotz Nano Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of DTZ, pending the release of an announcement regarding a capital raising.

The suspension of trading in the securities of Dotz Nano Limited will be lifted from the commencement of trading on Thursday, 24 May 2018, following the release of correspondence arising from an ASX query.

The company announces the retraction of the previously announced achievement of Performance Share milestones. Accordingly, the conversion of the 22 million Performance Shares as previously announced will not proceed. The reason for the retraction was due to there being some confusion regarding the correct date by which the relevant milestone for the performance rights needed to be satisfied. The Board of Directors can now confirm that the Company has not achieved Milestone A within the 18 month period since the issue date of 31 October 2016.

The company issues a response to ASX Query.

The securities of Dotz Nano Limited will be suspended from quotation immediately, in accordance with Listing Rule 17.3, pending a response to an ASX query letter. The securities will remain suspended until ASX receives a satisfactory response to its query.

The suspension of trading in the securities of Dotz Nano Limited will be lifted immediately, following the release by the Company of an announcement in relation to a capital raising.

The company has received firm commitments to raise $1,500,000 via a placement of 12,500,000 shares to sophisticated investors. The shares will be issued under the company's existing capacity. Dotz Nano will also be issuing, subject to any shareholder approval that may be required, up to 10,000,000 unlisted options exercisable at $0.20 and expiring two years from the date of issue.

The company requests an extension of the voluntary suspension until it makes the announcement regarding a capital raising to the market, which is expects to make on or before the commencement of trading on 26 July 2017.

The securities of Dotz Nano Limited will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement in relation to a capital raising.

Dotz Nano Limited will be reinstated to official quotation as from 10am AEDT on Tuesday 15 November 2016 following the Company's compliance with listing rule 11.1.3 and chapters 1 and 2 of the ASX Listing Rules. 49,034,930 ordinary shares fully paid   Security Code:     DTZ

name changed from Northern Iron Limited